Rita Turpin, Ruixian Liu, Pauliina M Munne, Aino Peura, Jenna H Rannikko, Gino Philips, Bram Boeckx, Natasha Salmelin, Elina Hurskainen, Ilida Suleymanova, July Aung, Elisa M Vuorinen, Laura Lehtinen, Minna Mutka, Panu E Kovanen, Laura Niinikoski, Tuomo J Meretoja, Johanna Mattson, Satu Mustjoki, Päivi Saavalainen, Andrei Goga, Diether Lambrechts, Jeroen Pouwels, Maija Hollmén, Juha Klefström
BACKGROUND: Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on the tumor immune microenvironment (TIME). Therefore, there is a clear need for pharmacologically tractable models of the TIME to dissect its influence on mono- and combination treatment response at the individual level. METHODS: Here we establish a patient-derived explant culture (PDEC) model of breast cancer, which retains the immune contexture of the primary tumor, recapitulating cytokine profiles and CD8+T cell cytotoxic activity...
April 11, 2024: Journal for Immunotherapy of Cancer